Michael J. Evans
YOU?
Author Swipe
View article: Data from Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies
Data from Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies Open
Antibody-based therapies have emerged as a powerful strategy for the management of diverse cancers. Unfortunately, tumor-specific antigens remain challenging to identify and target. Recent work established that inhibitor-modified peptide a…
View article: Supplementary Data from Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies
Supplementary Data from Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies Open
Supplemental Data and Figures
View article: Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies
Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies Open
Antibody-based therapies have emerged as a powerful strategy for the management of diverse cancers. Unfortunately, tumor-specific antigens remain challenging to identify and target. Recent work established that inhibitor-modified peptide a…
View article: Low cost, high temporal resolution optical fiber-based γ-photon sensor for real-time pre-clinical evaluation of cancer-targeting radiopharmaceuticals
Low cost, high temporal resolution optical fiber-based γ-photon sensor for real-time pre-clinical evaluation of cancer-targeting radiopharmaceuticals Open
Cancer radiopharmaceutical therapies (RPTs) have demonstrated great promise in the treatment of neuroendocrine and prostate cancer, giving hope to late-stage metastatic cancer patients with currently very few treatment options. These thera…
View article: SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy
SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy Open
Given the recent advances in clinical use of TRT in prostate cancer, the proposed system is verified in a prostate cancer mouse model using 177Lu-PSMA-617.
View article: Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial Open
Prostate Cancer Foundation, National Cancer Institute, Novartis Pharmaceuticals, and Merck.
View article: Chemoenzymatic Syntheses of Fluorine-18-Labeled Disaccharides from [<sup>18</sup>F] FDG Yield Potent Sensors of Living Bacteria <i>In Vivo</i>
Chemoenzymatic Syntheses of Fluorine-18-Labeled Disaccharides from [<sup>18</sup>F] FDG Yield Potent Sensors of Living Bacteria <i>In Vivo</i> Open
Chemoenzymatic techniques have been applied extensively to pharmaceutical development, most effectively when routine synthetic methods fail. The regioselective and stereoselective construction of structurally complex glycans is an elegant …
View article: Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects
Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects Open
Molecularly targeted radionuclide therapies (TRTs) struggle with balancing efficacy and safety, as current strategies to increase tumor absorption often alter drug pharmacokinetics to prolong circulation and normal tissue irradiation. Here…
View article: Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [<sup>18</sup>F]FDG yield potent sensors of living bacteria<i>in vivo</i>
Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [<sup>18</sup>F]FDG yield potent sensors of living bacteria<i>in vivo</i> Open
Chemoenzymatic techniques have been applied extensively to pharmaceutical development, most effectively when routine synthetic methods fail. The regioselective and stereoselective construction of structurally complex glycans is an elegant …
View article: Figure S4 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S4 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression in locally-advanced vs metastatic patients, from the IMvigor210 dataset. p=0.55 by Wilcoxon test, n=316 patients.
View article: Figure S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression by pathologic stage in the TCGA dataset. p=0.72 by Kruskal-Wallis test.
View article: Figure S9 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S9 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
A plot showing the mean tumor volume for the vehicle and treated arms from the antitumor assessment study in mice bearing UMUC3 xenografts. The differences in mean between treatment arms was found to be significant (P < 0.001) using an unp…
View article: Figure S6 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S6 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression is not associated with overall survival. Kaplan–Meier survival analyses were performed on quartiles of CDCP1 mRNA expression with overall survival as the endpoint. p > 0.05 in both public datasets for which overall su…
View article: Figure S9 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S9 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
A plot showing the mean tumor volume for the vehicle and treated arms from the antitumor assessment study in mice bearing UMUC3 xenografts. The differences in mean between treatment arms was found to be significant (P < 0.001) using an unp…
View article: Data from Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer
Data from Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer Open
Noninvasive biomarkers that detect the activity of important oncogenic drivers could significantly improve cancer diagnosis and management of treatment. The goal of this study was to determine whether 68Ga-citrate (which avidly binds to ci…
View article: Figure S2 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S2 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression by clinical stage in the Seiler dataset. p=0.12 by Kruskal-Wallis test.
View article: Figure S8 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S8 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA is not correlated NECTIN4 or TROP2 mRNA, related to Figure 2C. Spearman correlation analyses were performed between CDCP1 and NECTIN4 or TROP2 for the Seiler, Sjodahl 2017, and Sjodahl 2012 datasets, with p values and correlatio…
View article: Table S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Table S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA is overexpressed in basal/squamous subtypes of bladder cancer, related to Figure 1A-D. Pairwise comparisons of CDCP1 expression between bladder cancer consensus subtypes using the Wilcoxon rank-sum test across four different dat…
View article: Figure S3 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S3 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 protein expression by clinical stage using the tissue microarray. p=0.32 by Kruskal-Wallis test.
View article: Data from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Data from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen Open
Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clin…
View article: Figure S8 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S8 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA is not correlated NECTIN4 or TROP2 mRNA, related to Figure 2C. Spearman correlation analyses were performed between CDCP1 and NECTIN4 or TROP2 for the Seiler, Sjodahl 2017, and Sjodahl 2012 datasets, with p values and correlatio…
View article: Figure S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression by pathologic stage in the TCGA dataset. p=0.72 by Kruskal-Wallis test.
View article: Figure S4 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S4 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression in locally-advanced vs metastatic patients, from the IMvigor210 dataset. p=0.55 by Wilcoxon test, n=316 patients.
View article: Table S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Table S1 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA is overexpressed in basal/squamous subtypes of bladder cancer, related to Figure 1A-D. Pairwise comparisons of CDCP1 expression between bladder cancer consensus subtypes using the Wilcoxon rank-sum test across four different dat…
View article: Data from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Data from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen Open
Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clin…
View article: Figure S7 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S7 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
A summary of the data from saturation binding assays used to calculate Bmax and receptor number per cell for bladder cancer cell lines. The data are representative of two independent assays. Data are reported as mean ± standard deviation.
View article: Figure S5 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S5 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression by site of biopsy, from the IMvigor210 dataset. p = 0.075 by Kruskal-Wallis test, n=348 samples
View article: Figure S5 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S5 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
CDCP1 mRNA expression by site of biopsy, from the IMvigor210 dataset. p = 0.075 by Kruskal-Wallis test, n=348 samples
View article: Figure S10 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Figure S10 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer Open
A plot showing the mean tumor volume for the vehicle and treated arms from the antitumor assessment study in mice bearing UMUC3 xenografts. The differences in mean between treatment arms was found to be significant (P < 0.001) using an unp…